The Latest
-
Paul Marotta/Sipa USA/Newscom
Making MovesIn the fallout from Aduhelm, Biogen’s leadership shakeup continues
The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.
-
Stock via Getty Images
PharmaVoice 100The PharmaVoice 100 — Who makes the cut
What we’re looking for in each new class of honorees.
-
Permission granted by Chris Fox Novartis Gene Therapies
Podcast
Woman of the Week: Novartis Gene Therapies’ Chris Fox
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...
-
Permission granted by BeiGene
ProfileA rising oncology powerhouse in China, BeiGene looks to strengthen its international punch
To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.
-
Stock via Getty Images
ProfileThe power of connections for a startup CEO
Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.
-
Chip Somodevilla/Staff/Getty Images News via Getty Images
Biden doubles down on drug pricing in 2024 budget — but boosts R&D
The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.
-
Permission granted by Babson Diagnostics
Q&ABabson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
-
Permission granted by Murray Aitken/IQVIA Institute
Q&AIQVIA’s OG of data analytics on the latest clinical trial trends
IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.
-
Permission granted by Faeth
Q&A // Biotech SpotlightWhile many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer
The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.
-
iStock via Getty Images
Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time
Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.
-
Stock via Getty Images
Targeting the new ‘Golden Girls’
With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.
-
Permission granted by Amy Ripka Lucy Therapeutics
Podcast
Woman of the Week: Lucy Therapeutics’ Amy Ripka
How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.
-
Samara Heisz via Getty Images
Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?
The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?
-
Stock via Getty Images
3 keys to good storytelling in pharma
The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.
-
Stock via Getty Images
Why layoffs are not the answer to biopharma’s troubled market
As companies look to cut costs, an EY analyst urges them to consider not cutting staff.
-
Stock via Getty Images
FDA ups generics and biosimilar approvals for a shot at lower drug costs
As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022.
-
Stock via Getty Images
PharmaVoice 100 honorees: Where are they now?
How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles.
-
iStock via Getty Images
Q&A // First 90 DaysThe ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
-
Christoph Burgstedt via Getty Images
Q&A // Biotech SpotlightLaunched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology
With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.
-
Stock via Getty Images
Do R&D costs justify the price of drugs? Nope, new study says
A BMJ study found that spending on drug sales vastly outstripped spending on drug development.
-
Permission granted by Cindy Dunkle Denali Therapeutics
Podcast
Woman of the Week: Denali Therapeutics’ Cindy Dunkle
As chief people officer, Dunkle is harnessing the company’s unique culture to foster innovation.
-
Stock via Getty Images
Multimillion-dollar therapies are changing how payers foot the bill
With more gene therapies headed to market, novel payment methods are emerging from regulators and academia.
-
Sarah Silbiger via Getty Images
Reata’s stock plummets amid sudden FDA neuro office shakeup
The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.
-
Who is Vivek Ramaswamy — the biotech entrepreneur turned presidential candidate?
The former CEO of Roivant, who became the face of the “anti-woke” business movement, is now running for the 2024 Republican presidential nomination. Here’s what he stands for.
-
iStock via Getty Images
As clinical trials face a hiring crunch, here’s how research organizations can pivot
Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.
